BIO.B vs. KEYS, VLTO, TER, FTV, RVTY, AVTR, NVMI, MIR, VNT, and CAMT
Should you be buying Bio-Rad Laboratories stock or one of its competitors? The main competitors of Bio-Rad Laboratories include Keysight Technologies (KEYS), Veralto (VLTO), Teradyne (TER), Fortive (FTV), Revvity (RVTY), Avantor (AVTR), Nova (NVMI), Mirion Technologies (MIR), Vontier (VNT), and Camtek (CAMT). These companies are all part of the "measuring and control equipment" industry.
Bio-Rad Laboratories vs. Its Competitors
Bio-Rad Laboratories (NYSE:BIO.B) and Keysight Technologies (NYSE:KEYS) are both measuring and control equipment companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, profitability, risk, earnings and dividends.
Bio-Rad Laboratories has a net margin of 12.50% compared to Keysight Technologies' net margin of 10.36%. Keysight Technologies' return on equity of 19.53% beat Bio-Rad Laboratories' return on equity.
Keysight Technologies has a consensus target price of $187.38, indicating a potential upside of 15.45%. Given Keysight Technologies' stronger consensus rating and higher probable upside, analysts clearly believe Keysight Technologies is more favorable than Bio-Rad Laboratories.
In the previous week, Keysight Technologies had 16 more articles in the media than Bio-Rad Laboratories. MarketBeat recorded 16 mentions for Keysight Technologies and 0 mentions for Bio-Rad Laboratories. Keysight Technologies' average media sentiment score of 1.13 beat Bio-Rad Laboratories' score of 0.00 indicating that Keysight Technologies is being referred to more favorably in the news media.
Bio-Rad Laboratories has a beta of 0.81, suggesting that its stock price is 19% less volatile than the S&P 500. Comparatively, Keysight Technologies has a beta of 1.18, suggesting that its stock price is 18% more volatile than the S&P 500.
0.0% of Bio-Rad Laboratories shares are owned by institutional investors. Comparatively, 84.6% of Keysight Technologies shares are owned by institutional investors. 28.4% of Bio-Rad Laboratories shares are owned by insiders. Comparatively, 0.6% of Keysight Technologies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Keysight Technologies has higher revenue and earnings than Bio-Rad Laboratories. Bio-Rad Laboratories is trading at a lower price-to-earnings ratio than Keysight Technologies, indicating that it is currently the more affordable of the two stocks.
Summary
Keysight Technologies beats Bio-Rad Laboratories on 13 of the 16 factors compared between the two stocks.
Get Bio-Rad Laboratories News Delivered to You Automatically
Sign up to receive the latest news and ratings for BIO.B and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding BIO.B and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BIO.B vs. The Competition
Bio-Rad Laboratories Competitors List
Related Companies and Tools
This page (NYSE:BIO.B) was last updated on 10/20/2025 by MarketBeat.com Staff
